Cargando…
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at significantly lower concentrations than the plasma trough levels achieved by the dosage adopted for influenza treatment and exhibits effic...
Autores principales: | Shiraki, Kimiyasu, Sato, Noriaki, Sakai, Kaoru, Matsumoto, Shirou, Kaszynski, Richard H., Takemoto, Masaya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806403/ https://www.ncbi.nlm.nih.gov/pubmed/35121001 http://dx.doi.org/10.1016/j.pharmthera.2022.108121 |
Ejemplares similares
-
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
por: Shiraki, Kimiyasu, et al.
Publicado: (2020) -
Novel Polymorph of Favipiravir—An Antiviral Medication
por: Goloveshkin, Alexander S., et al.
Publicado: (2021) -
Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022) -
Favipiravir – a Modern Antiviral Drug: Synthesis and Modifications
por: Titova, Yulia A., et al.
Publicado: (2020) -
Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
por: Mayor, Jennifer, et al.
Publicado: (2021)